Rebecca Roma
Psychiatry · Pittsburgh, PANPI 1366439747
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,668,222 of the $3,326,695 with a category attached, or 80.2%. 11 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 28.9% of the total. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4,270 payments — averaging $779.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$961K
- Alkermes, Inc.$737K
- Neurocrine Biosciences, Inc.$574K
- Johnson & Johnson$516K
- Teva Pharmaceuticals USA, Inc.$279K
- E.r. Squibb & Sons, L.L.C.$112K
- plus $147K from 5 others
What the payments were for
- Consulting fees$203,0396%
- Speaking & faculty fees$2,668,22280%
- Travel & lodging$388,35212%
- Food & beverage$67,0822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 1,457 | $961,274 |
| Alkermes, Inc. | 1,028 | $737,180 |
| Neurocrine Biosciences, Inc. | 662 | $574,359 |
| Johnson & Johnson | 613 | $515,528 |
| Teva Pharmaceuticals USA, Inc. | 222 | $279,470 |
| E.r. Squibb & Sons, L.L.C. | 151 | $111,939 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 107 | $105,137 |
| H. Lundbeck A S | 4 | $30,201 |
| Lundbeck LLC | 15 | $10,607 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 7 | $735 |
| AbbVie(2 entities) | 4 | $265 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,539,958
- LYBALVI$1,323,741
- ABILIFY MAINTENA$578,570
- INGREZZA$564,692
- INVEGA SUSTENNA$495,648
- INVEGA TRINZA$492,118
- REXULTI$427,110
- ARISTADA INITIO$361,507
- ABILIFY ASIMTUFII$187,123
- AUSTEDO$116,918
- CAPLYTA$103,416
- COBENFY$96,846
- UZEDY$90,352
- Austedo XR$68,897
- SPRAVATO$10,329
- INVEGA$2,520
- VYEPTI$670
- VRAYLAR$200
How this compares
$3,326,695 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 15 | $242 |
| Clonazepam | 12 | $73 |
| Zolpidem Tartrate | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Pittsburgh
- Mayer AyyashPittsburgh$714K
- Leon RavinPittsburgh$106K
- Barbara NightingalePittsburgh$93K
- Mark FullerPittsburgh$38K
- Jasbir KangPittsburgh$16K
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.